Precigen's Inxn-4001 investigational therapy uses a nonviral plasmid to express SDF-1α, VEGF165, and S100A1 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling. The therapy targets "molecular mechanisms of pathological myocardial remodelling and is delivered to the ventricle via retrograde coronary sinus infusion (RCSI)," it said.

The phase I trial included 12 chronic heart failure patients treated in two cohorts who received different amounts of the drug, then were evaluated after six months. The Inxn-4001 infusions were well-tolerated and no adverse events were attributed to them, the company said. Secondary findings demonstrated that 50% of patients showed improved results in a six-minute walk test at six-month follow up, according to the firm.

Additional clinical results are expected within the next 12 months.

Taysha gets $95M in financing to advance gene therapies
Taysha Gene Therapies has closed on $95 million in series B financing to advance gene therapies for monogenic central nervous system diseases.

Kriya establishes internal gene therapy manufacturing capacity
Kriya Therapeutics has secured a 51,000-sq-ft facility in Research Triangle Park, NC, to establish internal operational manufacturing of its pipeline...

Tessera introduces new genome engineering strategy
Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing...